Sign In
Buy DNLI
$19.66
+0.310 (+1.60%)
At Close: Jun 03, 2026
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
02:43pm, Monday, 17'th Oct 2022 Zacks Investment Research
Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
12:00pm, Monday, 03'rd Oct 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Denali Therapeutics Inc. (Nasdaq: DNLI) today announced that dosing has commenced i
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?
11:30am, Thursday, 29'th Sep 2022 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
09:09am, Thursday, 29'th Sep 2022 Benzinga
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The tria
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?
09:02am, Thursday, 29'th Sep 2022
Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further p
Netflix, Biogen And Other Big Gainers From Wednesday
07:45am, Thursday, 29'th Sep 2022 Benzinga
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.
Acumen Pharmaceuticals, Inc. (NAS
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
04:40pm, Wednesday, 28'th Sep 2022 Benzinga
Gainers
Prothena Corporation plc (NASDAQ: PRTA) shares climbed 76.4% to $54.54 after Biogen and Eisai Co. Ltd. announced late Tuesday positive results from a late-stage study of their Alzheimer’s
Why Is Denali Therapeutics Inc. (DNLI) Down 27.4% Since Last Earnings Report?
03:30pm, Wednesday, 07'th Sep 2022 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Denali Therapeutics Inc. (DNLI) Down 27.4% Since Last Earnings Report?
12:48pm, Wednesday, 07'th Sep 2022
Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock?
3 Companies Growing Revenue Fast
02:23pm, Wednesday, 10'th Aug 2022
S&P 500 stocks have posted average growth of 6.54% in annual total revenue from 2017 to 2021. The benchmark index for the U.S. stock market closed at 4,122.47 on Tuesday, up nearly 70% over the past f
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus
02:53pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus
12:02pm, Tuesday, 09'th Aug 2022
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
09:25pm, Monday, 08'th Aug 2022 Zacks Investment Research
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates
06:48pm, Monday, 08'th Aug 2022
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Biotech Disruptor Ginkgo Bioworks Is Well-Positioned for the Future
09:50am, Friday, 05'th Aug 2022 The Motley Fool
Beaten down from its highs late last year, cell engineering company Ginkgo Bioworks now looks primed to divide and conquer.
